Advertisement

Advertisement

SITC 2022

Lung Cancer

Study Finds Immune Checkpoint Inhibitors Safe and Effective for Patients Living With HIV Who Have NSCLC

Immune checkpoint inhibitors are safe and effective for people living with HIV who have metastatic non–small cell lung cancer (NSCLC), according to data presented at the 2022 Society for Immunotherapy...

Head and Neck Cancer

Cabozantinib Plus Atezolizumab Warrants Further Study in Treatment of Advanced Head and Neck Cancer

A challenging patient population with advanced head and neck cancer may have a new treatment option, according to data presented during the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeti...

Bladder Cancer

Study Reports Activity With Oncolytic Vaccine Plus Pembrolizumab in BCG-Unresponsive Bladder Cancer

An oncolytic therapy delivered within the urinary bladder in combination with pembrolizumab has yielded high complete response rates in patients with bacillus Calmette-Guérin (BCG)-unresponsive bladde...

CNS Cancers
Immunotherapy

Expert Point of View: Rimas V. Lukas, MD

Rimas V. Lukas, MD, a neuro-oncologist at Northwestern Medicine Lou and Jean Malnati Brain Tumor Institute, Chicago, praised the investigators’ willingness to explore relatively new areas of cancer re...

CNS Cancers
Immunotherapy

Study Finds Microbiome-Derived Vaccine Plus Nivolumab and Bevacizumab May Improve Outcomes in Recurrent Glioblastoma

A microbiome-derived therapeutic vaccine (EO2401) has demonstrated immune responses and anticancer activity in combination with nivolumab and bevacizumab in patients with recurrent glioblastoma, one o...

Immunotherapy

From the Clinic to the Lab: Overcoming Resistance to Immune Checkpoint Therapy

As a result of breakthroughs in immune checkpoint inhibitors over the past decade, immunotherapy has joined surgery, radiation therapy, and chemotherapy as one of the pillars of cancer treatment. Howe...

Skin Cancer
Immunotherapy

Expert Point of View: Ryan J. Sullivan, MD

Ryan J. Sullivan, MD, Associate Professor of Medicine at Harvard Medical School, and Associate Professor of Hematology/Oncology at Massachusetts General Hospital, Boston, told The ASCO Post that tumor...

Skin Cancer
Immunotherapy

Study Finds Lifileucel Active in Advanced Melanoma After Disease Progression on Immune Checkpoint Inhibitors

Cell therapy with tumor-infiltrating lymphocytes (TIL) may address an important unmet need for patients with difficult-to-treat melanoma after disease progression on immune checkpoint inhibitors, acco...

Bladder Cancer

Study Reports Activity With Oncolytic Vaccine Plus Pembrolizumab in BCG-Unresponsive Bladder Cancer

An oncolytic therapy delivered within the urinary bladder in combination with pembrolizumab has yielded the “best results seen in the field” in patients with bacillus Calmette-Guérin (BCG)-unresponsiv...

kidney cancer
immunotherapy

Sumanta Pal, MD, on Renal Cell Carcinoma: CRISPR-Engineered CAR T Cells in Advanced Disease

Sumanta Pal, MD, of the City of Hope Comprehensive Cancer Center, discusses phase I results from the COBALT-RCC study, a first-in-human clinical trial exploring CD70 CAR T-cell therapy in patients wit...

bladder cancer
immunotherapy

Roger Li, MD, on Bladder Cancer: Boosting Immune Checkpoint Blockade With an Oncolytic Adenovirus

Roger Li, MD, of the H. Lee Moffitt Cancer Center, discusses results from a phase II single-arm study of CG0070, a cancer-selective oncolytic adenovirus that creates mechanistic synergy with immune ch...

immunotherapy

Michael B. Atkins, MD, on Reconciling Differences in Phase II and III Immuno-oncology Trial Data

Michael B. Atkins, MD, of Georgetown Lombardi Comprehensive Cancer Center, explores recent clinical trials in immuno-oncology in which the phase III trial produced markedly different results from the ...

lung cancer
immunotherapy

Kishu Ranjan, PhD, on Non–Small Cell Lung Cancer: New Findings on a Biomarker and Immunotherapy Resistance

Kishu Ranjan, PhD, of Yale University School of Medicine, discusses his study findings, which identified a deficiency in the biomarker TAP2 as a prominent immune evasion mechanism in patients whose no...

lung cancer
immunotherapy

Jonathan Chen, MD, PhD, on NSCLC: Predicting Response to Immunotherapy

Jonathan Chen, MD, PhD, of Massachusetts General Hospital, discusses “immunity hubs” that interact with a reservoir of stem-like CD8 T cells and appear to be associated with subsequent response to ant...

skin cancer
immunotherapy

Saman Maleki, PhD, on Melanoma: Reducing Primary Resistance to Immunotherapy

Saman Maleki, PhD, of Canada’s Western University and Lawson Health Research Institute, discusses modifying the gut microbiome in patients with advanced melanoma to induce a response to anti–PD-1 ther...

breast cancer
immunotherapy

Julia Tchou, MD, PhD, on Triple-Negative Breast Cancer: Radiation Boost Plus Pembrolizumab

Julia Tchou, MD, PhD, of the University of Pennsylvania, discusses preliminary results of the phase Ib/II BreastVax study, which suggested a single preoperative pembrolizumab dose plus a tumor-targeti...

solid tumors
immunotherapy

Antoni Ribas, MD, PhD, on Solid Tumors: Safety and Efficacy of TCR T-Cell Therapy

Antoni Ribas, MD, PhD, of the University of California, Los Angeles, discusses a phase I study that used CRISPR gene editing to simultaneously “knock out” endogenous T-cell receptors and replace them ...

immunotherapy

Michael A. Postow, MD, on Using the Novel Radiotracer Crefmirlimab Berdoxam for Imaging to Assess Immunotherapy Responsiveness

Michael A. Postow, MD, of Memorial Sloan Kettering Cancer Center, discusses new findings on the correlation between CD8 cell PET imaging with zirconium-89–crefmirlimab berdoxam and CD8 cell immunohist...

cns cancers
immunotherapy

David Reardon, MD, on Glioblastoma: A Microbiome-Based Vaccine, Nivolumab, and Bevacizumab

David Reardon, MD, of Dana-Farber Cancer Institute, discusses phase I/II results from the EOGBM1-18/ROSALIE study, which showed the EO2401 vaccine plus nivolumab generated systemic immune responses co...

lung cancer
immunotherapy

Wade T. Iams, MD, on NSCLC: Combining an Antigen-Presenting Cell Activator With Pembrolizumab

Wade T. Iams, MD, of Vanderbilt University Medical Center, discusses phase II efficacy results from the first-line non–small cell lung cancer cohort of the TACTI-002 study. The results suggest that wh...

immunotherapy
lung cancer

Talal El Zarif, MD, and Abdul Rafeh Naqash, MD: For Patients Living With HIV and Cancer, New Data on Immune Checkpoint Inhibitors

Talal El Zarif, MD, of Dana-Farber Cancer Institute, and Abdul Rafeh Naqash, MD, of Stephenson Cancer Center at The University of Oklahoma, discuss the results of their cohort study of patients living...

Skin Cancer
Immunotherapy

New Phase I/II Data on the CD40 Antibody Sotigalimab in Combination With Pembrolizumab in Patients With Metastatic Melanoma

New data from an ongoing phase II trial evaluating first-line intratumoral administration of sotigalimab, a CD40 agonist antibody, in combination with systemic pembrolizumab, an anti–PD-1 antibody, in...

Lung Cancer
Immunotherapy

Immune Checkpoint Inhibitors for Patients Living With HIV: Safe and Effective in Metastatic NSCLC

Immune checkpoint inhibitors are safe and effective for people living with HIV who have metastatic non–small cell lung cancer (NSCLC), according to data presented by El Zarif et al at the Society for ...

Advertisement

Advertisement



Advertisement